Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 0.72 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ILK | Q13418 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30966559 | 0.88 | AHR (0.59) | APPGFERSULT1A1KDM4ENPC1 | |
| SCHEMBL19985005 | 0.88 | AHR (0.59) | APPGFERSULT1A1KDM4ENPC1 | |
| SCHEMBL30966572 | 0.88 | AHR (0.59) | APPGFERSULT1A1KDM4ENPC1 | |
| SCHEMBL5691118 | 0.86 | APP (0.68) | APPMAOBAXLGFERSULT1A1 | |
| SCHEMBL5691080 | 0.86 | APP (0.71) | APPMAOBAXLGFERSULT1A1 | |
| SCHEMBL5691307 | 0.86 | APP (0.68) | APPMAOBAXLGFERSULT1A1 | |
| SCHEMBL5691309 | 0.86 | APP (0.68) | APPMAOBAXLGFERSULT1A1 | |
| SCHEMBL4636886 | 0.86 | APP (0.68) | APPSULT1A1KDM4ENPC1GLA | |
| SCHEMBL13853342 | 0.84 | APP (1.00) | APPGFERSULT1A1KDM4ENPC1 | |
| SCHEMBL4592891 | 0.84 | APP (0.69) | APPKDM4ENPC1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910349-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009524-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | NR2E1, NR2E3, NR0B2 | APP 2819/4885MAOB 110/4885AXL 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.